Rapport’s RAP-219, licensed from J&J, hits Phase 2 bipolar mania goal, with registrational trials planned for 2H 2027.

Astellas partners with AI Proteins, paying up to $400M, to develop miniprotein therapies using AI. CEO Chris Bahl targets ...

A Massachusetts jury awards former Whitehead scientist David Sabatini $6M in his defamation suit against his accuser, who ...

Merck KGaA agrees to buy Silence Therapeutics for $1.3B, adding siRNA drug divesiran, which is headed to Phase 3 in polycythemia vera.

At the three-month point, 30.2% of patients treated with ABBV-466 met the primary endpoint of endoscopic remission.

ScionxBio signs first deal with Sanofi to screen mRNA candidates via its TERA platform. CEO Adi Gilboa-Geffen declined to ...

The most com­mon side ef­fects seen with ZL-1310 plus Tecen­triq in the study were ane­mia (42.2%), nau­sea (26.7%), ...

TriGemX Bio, formerly Kallyope, will go public via a $600M SPAC with TCGX, getting $246M to push its Phase 3 migraine drug ...

A health­care as­set and roy­al­ties hold­ing com­pa­ny is bring­ing a long-act­ing oral med­i­cine ap­proach back to life, res­ur­rect­ing a drug de­liv­ery plat­form that had ac­cu­mu­lat­ed more ...

China's Commerce Ministry proposes restricting export of cell/gene therapy, siRNA, and pathogen tech, while preserving drug ...

Welcome back to another edition of Endpoints Weekly. Thanks to everyone who came out to our AI Day event this week in New ...

Eli Lilly's neuroscience president Carole Ho expressed interest in ibogaine R&D at NYC's Psychedelic Healthcare Forum, ...